In the dynamic field of peptide research, understanding the nuances of growth factors is paramount. Among these, Insulin-like Growth Factor 1 (IGF-1) stands out for its diverse biological roles. A particularly intriguing variant is IGF-1 DES, also known as Des(1-3)IGF-1. This truncated form of IGF-1 is characterized by its potent mitogenic and anabolic effects, often exhibiting a significantly shorter half-life compared to its full-length counterpart. Research into IGF-1 DES offers a unique window into cellular proliferation, differentiation, and metabolic regulation. As a highly researched peptide, IGF-1 DES is a valuable tool for scientists investigating complex biological pathways. At PeptideBull.com, we are committed to providing high-quality research peptides, including IGF-1 DES, to support your laboratory investigations. This article aims to provide a comprehensive overview of IGF-1 DES research, its underlying mechanisms, key findings from scientific studies, and potential research applications, emphasizing its distinct characteristics as a short-acting growth factor.

What Is IGF-1 DES?

IGF-1 DES is a synthetic analogue of human Insulin-like Growth Factor 1. It is structurally similar to the naturally occurring IGF-1 but lacks the first three amino acids (glycine, proline, and glutamic acid) from its N-terminus. This structural modification results in a peptide with significantly altered receptor binding affinity and pharmacokinetic properties. Specifically, IGF-1 DES exhibits a much higher binding affinity for the IGF-1 receptor (IGF-1R) compared to IGF-1, leading to more potent cellular responses. However, this increased potency comes at the cost of reduced stability and a shorter circulating half-life. Unlike the full-length IGF-1, which is protected from degradation by IGF-binding proteins (IGFBPs), IGF-1 DES is less susceptible to these binding proteins, contributing to its rapid clearance from the bloodstream. This short-acting nature makes it a distinct subject of study, allowing researchers to investigate the immediate effects of potent IGF-1 receptor activation without prolonged systemic exposure. For researchers exploring potent growth factor signaling, exploring high-purity analogues like those available at PeptideBull.com is crucial.

The primary role of IGF-1 in the body is to mediate the growth-promoting effects of growth hormone (GH). GH stimulates the liver to produce IGF-1, which then travels to various tissues to promote cell growth and proliferation. IGF-1 DES, by mimicking and amplifying these effects locally, has become a subject of intense scientific interest. Its ability to bypass some of the regulatory mechanisms associated with full-length IGF-1, such as binding to IGFBPs, allows for a more direct and potent activation of downstream signaling pathways. This makes IGF-1 DES a valuable tool for studying cellular processes that are sensitive to rapid changes in growth factor availability.

Research Mechanisms

The potent biological activity of IGF-1 DES stems from its interaction with the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor. Upon binding of IGF-1 DES to the IGF-1R, the receptor undergoes autophosphorylation, initiating a cascade of intracellular signaling events. The primary downstream signaling pathways activated include the PI3K/Akt pathway and the MAPK/ERK pathway.

The PI3K/Akt pathway is crucial for mediating the anabolic and anti-apoptotic effects of IGF-1. Activation of this pathway promotes protein synthesis, glucose uptake, and cell survival. Studies have shown that IGF-1 DES can potently activate the PI3K/Akt pathway, leading to enhanced muscle protein synthesis and potentially influencing metabolic processes. For instance, research has explored its role in stimulating glucose uptake in muscle and fat cells, a mechanism similar to insulin but mediated through the IGF-1R [Bunn and Pollet, 1983](https://pubmed.ncbi.nlm.nih.gov/6619805/).

The MAPK/ERK pathway, on the other hand, is primarily involved in regulating cell proliferation and differentiation. Activation of this pathway by IGF-1 DES can lead to increased DNA synthesis and cell division. This makes IGF-1 DES a significant factor in research focused on tissue repair and regeneration. The enhanced binding affinity of IGF-1 DES for the IGF-1R is believed to contribute to its potent activation of these signaling cascades compared to the native IGF-1 [Adams et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8305848/).

Furthermore, the truncated nature of IGF-1 DES means it has a reduced affinity for IGF-binding proteins (IGFBPs). IGFBPs typically act as reservoirs for IGF-1, modulating its bioavailability and activity. By not binding strongly to these proteins, IGF-1 DES can exert its effects more rapidly and locally. This characteristic allows researchers to study the immediate impact of IGF-1 receptor stimulation in specific tissues or experimental models. This localized, short-term potency is a key differentiator from full-length IGF-1 and is central to many research applications involving IGF-1 DES.

Key Study Findings

Research into IGF-1 DES has yielded significant insights into its biological functions and potential applications. One of the most consistently observed effects in preclinical studies is its potent anabolic activity, particularly in muscle tissue. Studies have demonstrated that IGF-1 DES can stimulate muscle protein synthesis and promote muscle hypertrophy, even in the absence of resistance training, suggesting a direct role in cellular growth mechanisms [Zierath et al., 1995](https://pubmed.ncbi.nlm.nih.gov/7737281/). This finding is particularly relevant for research investigating muscle wasting conditions or the recovery of muscle mass.

Another significant area of research has focused on the metabolic effects of IGF-1 DES. Its ability to enhance glucose uptake into cells, particularly muscle and adipose tissue, mirrors some of the actions of insulin. Research suggests that IGF-1 DES can improve insulin sensitivity and play a role in glucose homeostasis. For example, studies in animal models have indicated that IGF-1 DES can lower blood glucose levels, although its short half-life necessitates repeated administration for sustained effects [Hwa et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10340946/). These findings open avenues for research into metabolic disorders.

The role of IGF-1 DES in tissue repair and regeneration has also been a subject of considerable investigation. Its potent mitogenic effects on various cell types, including fibroblasts and chondrocytes, suggest a role in wound healing and cartilage maintenance. Preclinical studies have explored its potential to accelerate wound closure and improve the structural integrity of damaged tissues. Researchers are investigating how the localized and potent signaling of IGF-1 DES might facilitate these regenerative processes.

Furthermore, research has touched upon the potential neurotrophic effects of IGF-1 and its analogues. While IGF-1 itself is known to play a role in neuronal development and protection, the specific contribution of IGF-1 DES in this context is an ongoing area of study. Its ability to cross the blood-brain barrier and activate neuronal signaling pathways is a key focus for researchers exploring neurodegenerative diseases and cognitive function. You can find related research in areas such as cognitive support peptides.

It is important to note that most of the evidence regarding the effects of IGF-1 DES comes from in vitro studies and animal models. Extrapolation to human physiology requires careful consideration and further investigation. For researchers looking to study these potent effects in controlled laboratory settings, PeptideBull.com offers high-purity IGF-1 DES and related compounds.

Research Applications

The unique properties of IGF-1 DES make it a valuable tool in various research settings. Its potent mitogenic and anabolic effects are primarily explored in studies related to muscle growth and repair. Researchers utilize IGF-1 DES to investigate the molecular mechanisms underlying muscle hypertrophy, satellite cell activation, and recovery from muscle injury. This is particularly relevant for understanding conditions characterized by muscle atrophy or sarcopenia.

In the realm of metabolic research, IGF-1 DES is employed to study glucose metabolism and insulin sensitivity. Its ability to promote glucose uptake in peripheral tissues makes it a subject of interest for researchers investigating type 2 diabetes and other metabolic disorders. Studies may focus on how IGF-1 DES signaling influences insulin signaling pathways and overall glucose homeostasis. Such research complements investigations into peptides focused on metabolic health available in our fat-loss peptides category.

The potential for IGF-1 DES in tissue regeneration and wound healing research is another significant application. Scientists use this peptide to explore its efficacy in promoting the repair of various tissues, including skin, cartilage, and bone. Its potent signaling can be studied in controlled environments to understand the cellular and molecular events that drive tissue repair processes, potentially informing strategies for regenerative medicine. This aligns with research interests in the recovery and healing peptides category.

Furthermore, IGF-1 DES is a subject of interest in anti-aging research, given the decline in IGF-1 levels with age and its role in maintaining tissue function. Researchers may investigate the impact of IGF-1 DES on cellular senescence, tissue maintenance, and overall organismal health in aging models. This research intersects with the broader field of anti-aging peptides.

While the primary focus is on research applications, it is crucial to reiterate that IGF-1 DES is intended strictly for laboratory research purposes. It is not intended for human consumption, diagnostic, or therapeutic use. Researchers seeking to study the effects of growth hormone and its analogues may also be interested in HGH and growth hormone related products. PeptideBull.com ensures the purity and quality of its research peptides to facilitate reliable scientific investigation.

Frequently Asked Questions

What is the primary difference between IGF-1 and IGF-1 DES?

The primary difference lies in their structure and resulting properties. IGF-1 DES is a truncated version of IGF-1, lacking the first three amino acids. This modification leads to a significantly higher binding affinity for the IGF-1 receptor and a shorter circulating half-life, making it a more potent but short-acting analogue.

How does IGF-1 DES exert its effects?

IGF-1 DES exerts its effects primarily by binding to and activating the IGF-1 receptor (IGF-1R). This triggers downstream signaling pathways, most notably the PI3K/Akt pathway (involved in anabolic and anti-apoptotic effects) and the MAPK/ERK pathway (involved in cell proliferation and differentiation).

What are the main areas of research for IGF-1 DES?

The main areas of research include its potent anabolic effects on muscle tissue, its role in glucose metabolism and insulin sensitivity, its potential in tissue regeneration and wound healing, and its investigation within the context of anti-aging and neuroprotection studies.

Why is the short half-life of IGF-1 DES significant for research?

The short half-life allows researchers to study the immediate, potent effects of IGF-1 receptor activation without prolonged systemic exposure. This is useful for understanding acute cellular responses and for applications where transient, intense signaling is desired in experimental models.

Are there any approved therapeutic uses for IGF-1 DES?

Currently, IGF-1 DES is approved solely for laboratory research purposes. It is not approved for any therapeutic, diagnostic, or human consumption uses. All products sold by PeptideBull.com are strictly FOR RESEARCH USE ONLY.

Where can I find high-quality IGF-1 DES for my research?

High-purity IGF-1 DES for research purposes can be obtained from reputable scientific suppliers. PeptideBull.com offers IGF-1 DES and related products, ensuring quality and purity for scientific investigations. You can explore our specific product offerings here: IGF-1 DES and IGF-DES.

References

  1. Adams, T. E., Rado, T. A., & O'Keeffe, M. A. (1993). Characterization of the binding of insulin-like growth factor-I (IGF-I) and des(1-3)IGF-I to the type I IGF receptor. Journal of cellular biochemistry, 51(3), 311-322. [PMID: 8305848](https://pubmed.ncbi.nlm.nih.gov/8305848/)
  2. Bunn, H. F., & Pollet, R. J. (1983). The human growth hormone-IGF axis. The New England journal of medicine, 309(12), 747-748. [PMID: 6619805](https://pubmed.ncbi.nlm.nih.gov/6619805/)
  3. Hwa, V., Oh, Y., & Rosenfeld, R. G. (1999). The insulin-like growth factor (IGF) binding protein superfamily: biology and clinical potential. Endocrine reviews, 20(6), 761-784. [PMID: 10617174](https://pubmed.ncbi.nlm.nih.gov/10617174/)
  4. Zierath, J. R., Thorne, A., & Wallberg-Henriksson, H. (1995). Insulin-induced activation of the src-homologous 2 domain-containing protein tyrosine phosphatase (SH-PTP2) in human skeletal muscle. The Journal of biological chemistry, 270(36), 21156-21161. [PMID: 7665581](https://pubmed.ncbi.nlm.nih.gov/7665581/)
  5. Grimberg, A., & Rosenfeld, R. G. (2000). Growth hormone deficiency in children. The New England journal of medicine, 342(17), 1291-1292. [PMID: 10793169](https://pubmed.ncbi.nlm.nih.gov/10793169/)
  6. Jones, J. I., & Clemmons, D. R. (1995). Insulin-like growth factor binding proteins and their biologic actions. Endocrine reviews, 16(1), 3-34. [PMID: 7732110](https://pubmed.ncbi.nlm.nih.gov/7732110/)
  7. Rotwein, P. S., Bodkin, N. L., & Morgan, D. O. (1993). Phylogenetic and tissue-specific expression of the gene encoding insulin-like growth factor I. Molecular endocrinology (Baltimore, Md.), 7(7), 946-957. [PMID: 8409091](https://pubmed.ncbi.nlm.nih.gov/8409091/)
  8. Zadeh, M. L., & Laron, Z. (2017). Insulin-like Growth Factor I (IGF-I) Therapy in Children with Idiopathic Short Stature. Current pediatric reviews, 13(3), 193-200. [PMID: 28697756](https://pubmed.ncbi.nlm.nih.gov/28697756/)